SK Life Science, Inc., the U.S. subsidiary of SK Biopharmaceuticals, is an innovative global pharmaceutical company focused on the research, development and treatment of central nervous system (CNS) disorders. The company has a pipeline of eight compounds in development for CNS disorders including epilepsy.

In 2020, SK life science launched its first product.

Our commitment to the epilepsy community

As long as there are unmet needs in epilepsy and the CNS community, we keep working. We explore the complex mysteries of the brain to find answers for patients, caregivers, and healthcare professionals, because you’re worth it.

Check out these resources we developed for the epilepsy community:

• STEPS Toward Zero: In partnership with the Epilepsy Foundation in 2021, we launched STEPS Toward Zero – a movement designed to educate, inspire, and activate the epilepsy community to reimagine their epilepsy treatment goals with the help of their doctors, starting with stronger conversations. As part of the movement and to encourage people with epilepsy to share what zero seizures means to them, we will donate $1 to the EF for every social post including #STEPSTowardZero, up to $15,000.
• Seize the Truth about Epilepsy Perceptions (STEP) Survey: In 2019, we fielded a nationwide survey conducted by Kantar Health of over 850 people including epilepsy patients, caregivers and healthcare providers, which revealed important disconnects among the three groups. These findings showed key areas that need to be addressed in order for open, honest discussions to take place. To learn more about the survey and its findings, view this infographic (Include downloadable link to PDF version of STEP Survey Infographic).

• S.T.E.P.S. Discussion Tool: Take the right S.T.E.P.S. to have stronger conversations with your healthcare provider and work together to reach your goals. Within the S.T.E.P.S. Discussion Tool, you will find useful information such as suggested questions and topics that can be used to guide your discussion, so together you and your healthcare provider can create a treatment plan that works for you.
  • For an English version of this tool, click here. 
  • For a Spanish version of this tool, click here.

• Ride Share Program: Results from a survey conducted by Kantar Health on behalf of SK Life Science, Inc., reveal that for people with epilepsy, transportation can be a significant challenge. Some people may even be restricted from driving, depending on the severity of their seizures and where they live.
  Through a partnership, SK Life Science, Inc. and the Epilepsy Foundation are providing Uber vouchers to those with epilepsy and their caregivers as well as working to spread awareness about the many challenges the 3.4 million people in the United States living with epilepsy face every day. To learn more about the Ride Share program for people with epilepsy and their caregivers, go to www.epilepsy.com/rideshare.